摘要
目的 观察同期放化疗治疗中晚期食管癌的近期疗效和毒副作用。方法 78例食管癌患者随机分为放化组、单放组 ,放化组 39例放疗同期应用 5 -Fu、DDP方案化疗 ,单放组 39例单纯放疗。放疗采用 6MV或 15MV -X线照射 ,中平面总剂量 (DT) 6 6～ 70Gy 33～ 35次 ;化疗共 4个周期 ,与放疗同期进行 2个周期 ,放疗结束后2个周期。结果 随访 3年 ,放化组和单放组近期疗效CR分别为 79%和 5 1% (P <0 .0 5 ) ,1、2、3年生存率分别为74 .4 %、5 1.2 %、35 .9%和 4 8.7%、30 .7%、2 0 .5 % (P <0 .0 1) ,放化组生存率明显高于单放组 (P <0 .0 5 )。但骨髓抑制、胃肠道反应放化组高于单放组 (P <0 .0 5 )。结论 同期放化疗对中晚期食管癌治疗有协同作用 。
Objective To evaluate the response and acute toxicity of concomitant radiochemotherapy for middle and advanced esophageal carcinomas.?Methods 78 cases of middle and advanced esophageal carcinoma were randomized into two groups ( n =39 each). One group were treated with radiotherapy combined with 5-Fu and DDP (R+C group); the other group were given radiotherapy alone (R group). 6 MV or 15 MV X-ray was administrated conventionally, with a total dose of 66～70 Gy/33～35F. 4 cycles of chemotherapy were given, with two combined with radiotherapy, the other two given after the radiotherapy. All patients were followed up for 3 years.?Results The immediate complete response (CR) in R+C group and R group was 79% and 51%, respectively ( P <0.05). The R+C group showed higher 1-, 2- and 3-year survival rates than R group (74.4%, 51.2% and 35.9% vs. 48.7%, 30.7% and 20.5% respectively, P <0.01). However, the side effects (bone marrow suppression and gastrointestinal irritation ) were more serious in the R+C group ( P <0.05).?Conclusion?Concomitant radiotherapy and chemotherapy for the middle and advanced esophageal carcinomas are synergetic in action, and further clinical study on this regimen is worth while.
出处
《徐州医学院学报》
CAS
2003年第5期434-436,共3页
Acta Academiae Medicinae Xuzhou
